---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-120141"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:30:44.403202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3

## Summary
- 18 patients enrolled; 17 remain on therapy; safety consistent with known profile.
- 6 of 8 patients at Month 3 achieved BMI reduction; 3 of 5 at Month 6 saw BMI reduction.
- 6 of 7 evaluable patients at Month 3 had meaningful hyperphagia (HQ-CT) score reduction.
- Company plans to advance setmelanotide into Phase 3 registrational trial in PWS.
- Initiated Phase 1 Part D of weekly MC4R agonist RM-718 in up to 20 PWS patients.

## SEC filing metadata
- accession: 0001104659-25-120141
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/0001104659-25-120141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/rytm-20251211x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-120141
- JSON: https://secwatch.observer/filing/0001104659-25-120141.json
- Plain text: https://secwatch.observer/filing/0001104659-25-120141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.